US › Healthcare

Prelude Therapeutics Inc (PRLD)

US · Healthcare · Biotechnology

$3.26-1.81%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$5.7M

Net profit

$-13.9M

EPS

$-0.14

EPS estimate

$-0.17

Net margin

-244.1%

EPS came in at -0.14 against a street estimate of -0.17 — a beat of 17.6%.

Key statistics

Market cap

$283.5M

Forward P/E

0.0

P/B

2.57

Book value

$1.30

EPS (TTM)

$-0.73

52-week high

$6.83

52-week low

$1.16

50-day MA

$4.91

200-day MA

$3.94

Beta

0.96

Analyst view

Analysts rate Prelude Therapeutics Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $9.20.

Shareholding

Insiders

13.76%

Institutions

76.42%

Largest institutional holders

Fund	Stake
Orbimed Advisors LLC	17.20%
Baker Bros Advisors LP	12.69%
RA Capital Management, LLC	8.11%
Soleus Capital Management, L.P.	4.23%
Kynam Capital Management, LP	3.03%
Vanguard Capital Management, LLC	2.52%
BlackRock Inc	2.25%
Sphera Funds Management Ltd.	1.28%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Prelude Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.